ArticleNPJ precision oncology2025
Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04172402 (A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Who cites it
2 citing papers in PubMed.
- MicroRNA-425-3p: A Promising Biomarker and Candidate for Pharmacological Intervention in Neuropsychiatric Disabilities with Relevance to Major Depressive Disorder.Neuropsychiatric disease and treatment · 2026Review
- MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Circulating microRNAs (miRNAs) have not been investigated as predictive biomarkers in patients with advanced biliary tract cancer (ABTC) who received chemoimmunotherapy. In the single-arm phase II T1219 trial, 46 patients with ABTC received first-line nivolumab, gemcitabine, and S-1 treatment. Plasma samples were prospectively collected at baseline and 6 weeks after treatment for miRNA profiling. Among the 167 miRNAs analyzed, the baseline levels of hsa-miR-16-5p, hsa-miR-93-5p, and hsa-miR-126-3p were significantly elevated in the responders. High hsa-miR-16-5p expression was correlated with longer progression-free survival (hazard ratio [HR] = 0.44, 95% confidence interval [CI] = 0.12-0.85, p = 0.025) and overall survival (HR = 0.34, 95% CI = 0.07-0.7, p = 0.01). Post-treatment miRNA changes (e.g., hsa-miR-129-5p and hsa-miR-1254) were observed but were not significantly associated with survival. This study identified a three-miRNA signature with potential predictive value for chemoimmunotherapy in ABTC. Trial registration: NCT04172402, date of registration 2019/11/18.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.